Objective To investigate the efficacy of Yiqi Huoxue Powder in treating patients with MCI due to Alzheimer’s Disease(AD)in terms of cognition,daily living abilities,and HDS-R scores.Methods A total of 98 patients wit...Objective To investigate the efficacy of Yiqi Huoxue Powder in treating patients with MCI due to Alzheimer’s Disease(AD)in terms of cognition,daily living abilities,and HDS-R scores.Methods A total of 98 patients with MCI due to AD,admitted from August 2023 to August 2024,were randomly divided into an observation group and a control group,with 49 patients in each.The control group received Almitrine Bismylate and Rauwolfia Serpentina Tablet treatment,while the observation group received Yiqi Huoxue Powder in addition to the control group’s treatment.The treatment period was 4 weeks per course,for a total of 3 courses.Changes in cognition,daily living abilities,and HDS-R scores,as well as clinical efficacy,were observed before and after treatment in both groups.Results The total effective rate in the observation group was 96.8%,significantly higher than the 76.5%in the control group,with a statistically significant difference(P<0.05).After treatment,the observation group showed significantly higher scores in cognition,daily living abilities,and HDS-R compared to the control group,with statistically significant differences(P<0.05).Conclusion Yiqi Huoxue Powder demonstrates significant efficacy in treating MCI due to AD,significantly improving patients’cognition,daily living abilities,and HDS-R scores.展开更多
基金Sichuan Provincial Veterans Affairs Department Research Project:Investigation and Rehabilitation Treatment Research on Amnestic Mild Cognitive Impairment in Veterans with Post-Traumatic Stress Disorder,Project Number:CTYZ202403.
文摘Objective To investigate the efficacy of Yiqi Huoxue Powder in treating patients with MCI due to Alzheimer’s Disease(AD)in terms of cognition,daily living abilities,and HDS-R scores.Methods A total of 98 patients with MCI due to AD,admitted from August 2023 to August 2024,were randomly divided into an observation group and a control group,with 49 patients in each.The control group received Almitrine Bismylate and Rauwolfia Serpentina Tablet treatment,while the observation group received Yiqi Huoxue Powder in addition to the control group’s treatment.The treatment period was 4 weeks per course,for a total of 3 courses.Changes in cognition,daily living abilities,and HDS-R scores,as well as clinical efficacy,were observed before and after treatment in both groups.Results The total effective rate in the observation group was 96.8%,significantly higher than the 76.5%in the control group,with a statistically significant difference(P<0.05).After treatment,the observation group showed significantly higher scores in cognition,daily living abilities,and HDS-R compared to the control group,with statistically significant differences(P<0.05).Conclusion Yiqi Huoxue Powder demonstrates significant efficacy in treating MCI due to AD,significantly improving patients’cognition,daily living abilities,and HDS-R scores.
